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ABSTRACT 
We previously reported that OPG is involved in ischemic tissue neovascularization through 
the secretion of SDF-1 by pretreated-OPG endothelial colony-forming cells (ECFCs). As the 
vascularization is one of the key factor influencing the tumour growth and cancer cell 
dissemination, we investigated whether OPG was able to modulate the invasion of human 
MNNG-HOS osteosarcoma and DU145 prostate cancer cell lines in vitro and in vivo. Cell 
motility was analysed in vitro by using Boyden chambers. Human GFP-labelled MMNG-
HOS cells were inoculated in immunodeficient mice and the tumour nodules formed were 
then injected with OPG and/or FGF-2, AMD3100 or 0.9% NaCl (control group). Tumour 
growth was manually followed and angiogenesis was assessed by immunohistochemistry. In 
vitro, SDF-1 released by OPG-pretreated ECFCs markedly attracted both MNNG-HOS and 
DU145 cells and induced spontaneous migration of cancer cells. In vivo, tumour volumes 
were significantly increased in OPG-treated group compared to the control group and OPG 
potentiated the effect of FGF-2. Concomitantly, OPG alone or combined with FGF-2 
increased the number of new vasculature compared to the control group. Interestingly 
AMD3100, an inhibitor of SDF-1, prevented the in vivo effects of OPG induced by SDF-1 
This study provides experimental evidence that OPG promotes tumour development trough 
SDF-1/CXCR4 axis.  
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Highlights 
 
- OPG promotes tumour development  
 
- OPG is actively involved in tumour revascularization 
 
- SDF-1 released by OPG-pretreated endothelial colony-forming cells chemoattract cancer 
cells 
 
- SDF-1 induces spontaneous migration of osteosarcoma and carcinoma cell lines 
 
- OPG promotes tumour development trough SDF-1/CXCR4 axis 
 
 
Key Words: Osteoprotegerin, SDF-1, tumour angiogenesis, osteosarcoma, carcinoma. 
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1. INTRODUCTION 
Osteoprotegerin (OPG) is a member of the tumour necrosis factor (TNF) receptor superfamily 
which is involved in the regulation of bone remodelling, where it acts as a decoy receptor for 
nuclear factor-κB ligand (RANKL) [1]. OPG is considered as an ubiquitous factor which is 
then expressed in a variety of tissues and organs such as bone, heart, lung, liver, placenta, 
vessels and interacts with numerous cell types belonging to normal or cancerous tissues [2]. 
By its blocking activity of RANKL induced osteoclastogenesis, pre-clinical and clinical 
studies have investigated the therapeutic potential of recombinant OPG in osteolysis 
associated with cancer [1]. Preclinical studies demonstrated that the administration of 
recombinant OPG inhibited osteolysis associated with breast cancer metastasis or multiple 
myeloma and reduced cancer cell migration in vivo [3]. However, therapeutic use of OPG in 
bone tumours remains controversial due to its ability to bind and inhibit the TNF related 
apoptosis inducing ligand (TRAIL) resulting in the inhibition of tumour cells apoptosis [4]. 
OPG could be considered as a survival factor for tumour cells (reviewed in [5]). Hence, OPG 
has been described to be a survival factor of several types of cell tumour including 
osteosarcoma and prostate cancer cells [6]. 
Osteosarcoma, the most common primary malignant bone tumour, is defined as a 
malignant tumour with mesenchymal origin producing a malignant osteoid matrix [7]. Some 
are composed of largely fibroblastic cells, some show chondroid differentiation, and still 
others are highly vascular [8]. Whether the production of OPG by human osteosarcoma has 
been previously reported [9-11], carcinoma cells (e.g. prostate cancer) secrete also OPG [5] 
with a higher level in metastatic foci than in primary tumours [12]. Accordingly, serum OPG 
levels in prostate carcinoma patients have been positively correlated with the progression of 
the disease and the establishment of bone metastases [13]. These results strengthen strongly 
the potential involvement of OPG in cancer progression. 
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Angiogenesis is a key process contributing to tumour growth and progression. Various 
angiogenic cytokines, such as vascular endothelial growth factor (VEGF) and hepatocyte 
growth factor (HGF), are potent mitogens with angiogenic activity [14]. Hence, tumour 
angiogenesis has been extensively investigated in solid and haematological tumours, as well 
as in premalignant conditions, and numerous publications describing the link between tumour 
angiogenesis, metastasis, and overall survival are already available [reviewed in 15]. OPG 
should be added to the growing list of factors affecting tumour angiogenesis, as it has been 
found to be expressed in neovessels associated with malignant tumours and in angiogenic 
microvessels associated with inflammatory osteolytic diseases [16]. We previously 
demonstrated that OPG expressed by endothelial progenitor cells (EPCs) stimulated the 
migration of endothelial cells, then exerted a chemoattraction activity on these cells and 
stimulated the vascular cord formation in vitro and in vitro as shown in Matrigel plug assay 
[17]. OPG-mediated angiogenic activities were mediated by a MAPK, Akt and mTOR 
signaling cascade. OPG-induced proangiogenic activities were significantly blocked by 
preincubation with the CXCR4 antagonist AMD-3100 and by prior heparan sulphate 
proteoglycan disruption, demonstrating that OPG activities on EPCs were partly mediated by 
syndecan-1 and SDF-1/CXCR4 pathway [18]. Furthermore, OPG markedly enhanced 
functional properties of EPCs and these effects were correlated with overexpression and 
secretion of the chemokine stromal cell-derived factor-1 (SDF-1), a key player in the 
attraction of tumour cells [17]. Overall, these observations suggest a modulatory role of OPG 
in tumour revascularization. Indeed, SDF-1 possesses angiogenic properties and is involved in 
the outgrowth and metastasis of CXCR4-expressing tumours. Consequently, CXCR4 
inhibitors have been proposed as therapeutic agents to inhibit tumour growth and metastasis 
[19,20].  
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EPCs are bone marrow-derived circulating cells involved in postnatal vasculogenesis. 
These cells are recruited from bone marrow to sites of active revascularization, attracted by 
proangiogenic factors produced by the local inflammatory response [21]. A growing body of 
evidences indicates that neovascularization processes associated with tumour growth are 
partly supported by the recruitment of endogenous EPCs as well as their functional 
incorporation into new vasculatures and their paracrine effects [reviewed in 22].  
The aim of the present study was to determine whether SDF-1 released by endothelial 
colony-forming cells (ECFCs; a sub-population of EPCs) after OPG treatment can modulate 
human osteosarcoma MNNG/HOS and human prostate cancer DU145 cell lines, migration 
and chemotaxis in vitro. In addition, using a nude mouse model of human osteosarcoma 
xenografts, the effect of OPG on tumour growth and vascularization in vivo was investigated. 
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2. MATERIALS AND METHODS 
2.1. Reagents 
Recombinant human and mouse OPG were from R&D Systems (Lille, France). Mouse basic 
fibroblast growth factor (FGF-2) and stromal cell-derived factor-1 (SDF-1α) were from Abcys 
(Paris, France). AMD3100 and porcine skin gelatine (GEL) were from Sigma-Aldrich (Saint-
Quentin Fallavier, France). DMEM, NaCl and phosphate buffered saline (PBS) were provided 
by Invitrogen (Saint Aubin, France). Other biochemical reagents were from Sigma-Aldrich 
(Saint-Quentin Fallavier, France).  
 
2.2. Cancer cell lines and treatment 
The human DU145 prostate carcinoma and MNNG/HOS osteosarcoma cell lines purchased 
from American Tissue Cell Collection were maintained in DMEM supplemented with 10% 
foetal calf serum  (FCS, Gibco, France). When required, AMD3100 (10µg/mL) was added 30 
min before the treatment with conditioned media from OPG-pre-treated ECFCs. 
 
2.3. ECFCs isolation, culture and pretreatment 
Umbilical cord bloods were collected from consenting mothers. The study was approved by 
local ethics committee of "Hpital des Instructions et des Armes de Begin 
(France) (201008043234797) and protocol conformed to ethical guidelines of Declaration of 
Helsinki. ECFCs were isolated from human umbilical cord blood, expanded and 
characterized as previously described [23]. The endothelial cell phenotype was shown by 
double positivity for DiI-AcLDL uptake and BS-1 lectin binding. Further endothelial 
characterization was obtained by FACS analysis (FACSCalibur, Becton Dickinson) of 
combined expression of cell-surface antigens of the endothelial lineage, namely CD31, KDR, 
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Tie-2, CD144, CD34 and Flt-1. One day before experiments, ECFCs were growth-arrested 
for 18 hours in EBM2, 3% FCS and released from growth arrest by adding DMEM 5% FCS 
with or without 25 ng/mL of OPG at 37¡C for 48 hours. ECFCs conditioned media were then 
collected and centrifuged to be tested for cell migration assay, or kept at -80 ¡C to be further 
analysed for SDF-1 levels. All assays were performed in triplicate with cells cultured for less 
than 30 days.   
 
2.4. Chemotaxis assay 
Chemotaxis was analysed in 24-multiwell Boyden microchemotaxis chambers with 8 µm 
pore-size polyvinylpyrrolidone free polycarbonate Nucleopore filters (Costar, France). 
MNNG-HOS and DU145 were seeded in the upper chambers in their respective culture 
media (1.5 x 10
4
 cells/chamber) to allow the cell migration towards the control media 
(DMEM, 5% FCS), control media with 100 ng/mL of SDF-1 (positive control), OPG (25 
ng/mL) or supernatants of OPG pretreated ECFCs placed in the lower chambers. When 
required, before seeding, MNNG-HOS and DU145 were pretreated with AMD3100 (10 
µg/mL) for 30 min. Chemoattraction was analysed after 4 hours at 37¡C, 5% CO2. Cells 
remaining on the upper surface of the filters were mechanically removed, and the filters were 
then fixed with 1.1% formaldehyde and stained with Giemsa. The number of migrated cells 
was determined by manual counting under a high-power microscope.  
 
2.5. Migration assay 
As for chemotaxis assay, migration was examined in 24-multiwell Boyden microchemotaxis 
chambers. MNNG-HOS and DU145 were pretreated with the control media with or without 
100 ng/mL of SDF-1 (positive control), 25 ng/mL of OPG or with supernatants of OPG 
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pretreated ECFCs. When required, AMD3100 (10 µg/mL) was added 30 min before MNNG-
HOS and DU145 treatment. After 24 hours, 1.5 x 10
4
 control and pretreated-cells in 
suspension in the control media were placed in the upper chambers to follow the cell 
migration towards the same media placed in the lower chambers. Migration was allowed to 
proceed for 4 hours at 37¡C, 5% CO2. The number of migrated cells was determined as 
previously described for the chemotaxis assay. 
 
2.6. SDF-1 ELISA  
SDF-1 levels in supernatants of ECFCs were measured with enzyme-linked immunosorbent 
kits from R&D Systems
¨
 (France) according to the manufacturerÕs instructions.  
 
2.7. Animal experiments  
Animal care conformed to French guidelines (Services Vtrinaires de la Sant et de la 
Production Animale, Paris, France), and experiments were performed in keeping with the 
guidelines of Universit Paris Descartes and the Institutional Committee on Animal Care and 
Use (C75.06.02). Human osteosarcoma MNNG-HOS cells have been previously shown to 
rapidly divide in vivo, forming subcutaneous tumours after implantation into athymic nude 
mice. 4.5 x 10
6
 MNNG-HOS cells were injected subcutaneously in eight-week-old athymic 
nude mice (Elevage Janvier, France). Three to five days following injection, when tumours 
had reached approximately 3-4 mm
3
 in size, 100 µl of either 0.9% NaCl (negative control), 
mouse OPG (2 µg/kg), mouse FGF-2 (1.4 µg/kg) in the presence of absence of mouse OPG 
(2 µg/kg) were administered by direct intra-tumour injection (7 mice per group). This 
procedure was repeated twice a week for 3 weeks. To block the effects of OPG mediated by 
secreted SDF-1, the selective CXCR4 antagonist AMD3100 (0.5 mg/kg) or saline vehicle 
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(0.9% NaCl) was injected 30 minutes before OPG injection, followed by one intraperitoneal 
administration of AMD3100 (5 mg/kg) 8 hours later. Tumour volume was measured three 
times per week with calipers and each volume (V) was calculated according to the following 
formula: V=a×b2/2, where a and b are the largest and smallest perpendicular tumour 
diameters. Relative tumour volumes (RTV) were calculated from the following formula: 
RTV=(Vx/V1), where Vx is the tumour volume on day x and V1 is the tumour volume at 
initiation of treatment (day 1). After 3 weeks post initiation of treatment, host mice were 
euthanized, and tumour were excised and frozen by dipping for 30s in liquid nitrogen-chilled 
isopentane, and stored at -80C until sectioning and staining.  
 
2.8. Tissue processing and immunofluorescence  
For the analysis of tumour vascularization, frozen tumours were cut at 10 µm thickness. 
Sections were stained at room temperature for 1h with a primary antibody. When required, a 
secondary antibody coupled with Alexa Fluor¨ 555 or Alexa Fluor¨ 488 fluorochrome was 
used (Abcam, France). Rat Anti-CD31 monoclonal antibody (clone MEC 13.3), FITC-rabbit 
monoclonal anti-SMA antibody (clone 1A4) and polyclonal rabbit anti-von Willebrand factor 
antibody were purchased from BD Biosciences, Sigma (France) and Dako (France) 
respectively. The DNA marker, TOPRO-3 (Invitrogen) was then applied for 10 min at room 
temperature. Sections were mounted in glycerol/PBS (90/10: v/v) and images were recorded 
on a Leica TCS SP2 confocal microscope. Eight fields were examined per section. The vessel 
surface area and the number of vessels were quantified with Histolab software (Microvision 
Instruments, Evry France). Results are expressed as the vessel surface area (%) and the 
number of vessels per mm
2
.  
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2.9. Statistical analysis 
Data are expressed as means ± SEM of at least three independent experiments. Differences 
between groups were assessed by one-way ANOVA test fallowed by Mann-Whitney test, 
using the statistical software package GraphPad Prism, version 5. Results were considered 
statistically significant at the p-values ≤0.05. 
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3. RESULTS 
3.1. Endogenous SDF-1 released by OPG-pretreated ECFCs strongly attracts tumour 
cells 
We first measured the SDF-1 secretion by EFCFs cells in the presence or absence of OPG 
(Figure 1A). SDF-1 was basic produced spontaneously by ECFCs and OPG significantly 
upregulated the secretion of this soluble factor (Figure 1A). We then investigated the potential 
effect of OPG and conditioned media of OPG-pretreated ECFCs on MNNG-HOS cells 
chemotaxis and migration, to determine whether OPG might be involved in tumour cell 
dissemination. As shown in Figure 1B, osteosarcoma cells were attracted by 100 ng/mL of 
SDF-1 or 25 ng/mL of OPG (p<0.05 and p<0.01 respectively). Interestingly, MNNG-HOS 
cells were also markedly attracted by the conditioned media of OPG-pretreated ECFCs 
(p<0.001). In addition, OPG stimulated significantly MNNG-HOS cells chemotaxis in the 
same manner as SDF-1α (p<0.01). By using AMD3100, a specific antagonist of CXCR, we 
found that the effect exerted by conditioned media of OPG-pretreated ECFCs was partly due 
to the SDF-1 released by these cells under OPG treatment (p<0.01) As shown in Figure 1C, 
SDF-1 alone as well as SDF-1 released by ECFCs under OPG treatment are not only able to 
attract HOS, but can also act directly on these cells and induce their spontaneous migration, 
with a statistically significant effect (p<0.05 and p<0.01 respectively).  
Expression of the CXCR4 by prostate cancer DU145 cell line has been reported by several 
studies (expression confirmed by RT-qPCR in the present study, data not shown). Hence, the 
SDF-1/CXCR4 axis has been described as playing a key role metastasis of prostate cancer to 
bone [24]. OPG is also expressed by DU145 cells, its role in the lifecycle of these cells as 
well as in the communication between prostate cancer cells and bone cells is well established 
[25]. To determine whether the observed effects were specific to osteosarcoma cells, similar 
investigations were carried out on DU45 prostate carcinoma cells (Figure 2). As shown in 
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Figure 2, conditioned media of ECFCs pretreated or not with OPG attracted DU45 carcinoma 
cells. The supernatant of OPG-pretreated ECFCs induced a more potent attraction of DU45 
than SDF-1 alone (p<0.001). This activity was most likely due to SDF-1 released by ECFCs 
under OPG treatment, since it was reduced by 30% (p<0.05) when the SDF-1/CXCR4 
interaction was blocked by AMD3100. Pretreatment of DU145 cells with OPG or conditioned 
media of OPG-pretreated ECFCs did not affect their spontaneous migration (Data not shown). 
 
3.2. OPG enhances tumour growth in a murine xenograft model of osteosarcoma  
As described above, OPG showed greater effect on the MNNG-HOS cell motility in vitro. We 
further evaluate its effect in vivo in human osteosarcoma tumours developed in nude mice. 
The MNNG-HOS xenograft showed an appreciable growth starting from the fifth day after 
cell injection and doubled its volume after 3 days in all mice inoculated (Figure 3). To 
determine the effect of OPG on tumour growth in vivo, intra-tumour administration of 0.9% 
NaCl (control), 2 µg/kg of mouse OPG, or 1.4 µg/kg of mouse FGF-2 (positive control) was 
performed twice a week for 3 weeks, when the tumours reached a volume of approximately 3 
to 4 mm
3 
(Figure 3A). As shown in Figure 3B, intra-tumour administration induced a 
significant increase of subcutaneous tumour growth from 6 days post cell inoculation (p<0.01, 
at the endpoint Figure 3B).  
To investigate the possible synergy of OPG/FGF-2 as previously observed in 
neovascularization assays in vivo (14), we used the same model, injecting each mouse with 
1.4 µg/kg of murine FGF-2 alone or combined with 2 µg/kg of OPG. Analysis of the tumour 
growth showed enhanced tumour volume in OPG/FGF-2 treated mice (p<0.05 Figure 3C) 
compared to OPG alone (p<0.01 Figure 3C). No sign of distress or loss of weight in mice was 
evidenced.  
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Blood vessels are necessary to tumour growth by providing nutrients and oxygen. Double-
labelled fluorescent immunohistochemistry was undertaken to first determine whether CD31 
staining correlated with endothelial cell positive labelling. As shown in Figure 4A-C, von 
Willebrand Factor and CD31 colocalization was detected in endothelial cells in tumour blood 
vessels. Similarly, a-SMA  (smooth muscle) and CD31 (endothelial cells) were colocalized in 
large tumoural blood vessels of tumour plugs (Figure 4D-F). 
To evaluate the implication of OPG or associated with FGF-2 in tumour 
neovascularization, mice were sacrificed 24 days after the beginning of the treatment, and 
tumours were collected for immunofluorescent assays. The effects observed in Figure 3 were 
correlated with an increase of tumour vascularisation. As shown in Figure 5A,B, anti-CD31 
staining clearly revealed that the vessel density as well as the number of tumour microvessels 
were also increased in the FGF-2/OPG-treated group as compared with FGF-2 group (p<0.05) 
and OPG group (p<0.05). Furthermore, mice treated with OPG showed enhanced 
vascularization compared to control mice (Figure 5B, p<0.05).  
 
3.3. OPG pro-angiogenic activity associated to the tumour growth is dependent of SDF-
1/CXCR4 pathway 
To determine the role of SDF-1/CXCR4 axis in the OPG-induced tumour growth, 100 µl of 
either 0.9% NaCl (negative control), mouse OPG (2 µg/kg) with or without pre-injection of 
the AMD3100 antagonist for CXCR4 (0.5 mg/kg), were administered into the tumour tissues. 
Similarly to 0.9% NaCl, AMD3100 did not modulate the tumour growth when administered 
alone (Figure 6). As expected OPG increased significantly the tumour volume and 
interestingly AMD3100 abolished the OPG-increase tumour growth demonstrating that OPG-
dependent tumour growth was mediated by SDF-1/CXCR4 axis.   
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4. DISCUSSION 
OPG acts as a key regulator of bone metabolism by blocking osteoclast differentiation. 
Several in vitro and in vivo studies attributed OPG an important role in vascular biology [17, 
18, 27]. Thereby, there is growing evidence that it underlies a potential link between the 
osseous and vascular systems [27, 28]. One of the major discoveries about OPG was its ability 
to bind to and inhibit the activity of TRAIL; a cytotoxic protein inducing apoptosis mostly in 
tumour cells, suggesting that OPG production may provide cells with a survival advantage. In 
vitro studies using a number of different tumour types have supported this hypothesis 
(reviewed in [29, 30]). OPG expression is frequently altered in cancers. Investigations by 
several groups have shown that OPG levels hold promise as markers of cancer progression or 
as prognostic indicators[5]. 
The first aim of this study was to determine whether OPG may modulate the behaviour 
of  cancer cells and especially human osteosarcoma cells. So, we first examined a direct effect 
of OPG and effect of media conditioned by OPG pretreated ECFCs compared to SDF-1 on 
spontaneous migration and chemotaxis of MNNG-HOS cells in vitro. Media conditioned by 
OPG pretreated ECFCs attracted MNNG-HOS cells more strongly than SDF-1 treatment. 
OPG alone induced significantly HOS cells chemotaxis, raising the possibility that OPG can 
intervene both directly and indirectly to modulate osteosarcoma cells attraction. It should be 
noted that OPG pretreated ECFCs, in addition to SDF-1, may release other factors that can 
modulate cells chemotaxis, since MNNG-HOS cells treatment with AMD3100 not totally 
abolished the effect of supernatants of OPG pretreated ECFCs on cells chemotaxis. The other 
new element of this study is that the SDF-1 released by ECFCs under OPG treatment, at 
similar levels as a SDF-1 treatment, can act directly on the MNNG-HOS cells and induce 
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their spontaneous migration. We also found that SDF-1 released by ECFCs under OPG 
treatment significantly induces DU145 cells chemotaxis. Indicating that, the observed effects 
on HOS cells line can be heard on other tumour cell types. 
Metastasis are the leading cause of cancer-related death, around 13Ð27% of the 
osteosarcoma patients have detectable metastasis at diagnosis, whereas 40% will develop 
metastases at a later stage (reviewed in [31]). Molecular pathways contributing to 
osteosarcoma development and progression have recently been described and the role of 
several cytokines and chemokines was detailed (reviewed in [32]). Although the role of OPG 
and SDF-1 was not detailed in this revue, the significance of CXCR4 in metastasis 
development in osteosarcoma has been reported. In a mouse model, the tumour cells with 
CXCR4 receptor were chemoattracted by SDF-1, migrated through the lymphatic and 
vascular system, and arrested in SDF-1 rich organs like the bone and lungs [33]. A higher 
CXCR4 expression in metastasis compared with primary osteosarcoma was also reported 
[34]. In an analysis of Ewing sarcoma, another bone cancer, and in chondrosarcoma of bone, 
CXCR4 correlated with metastasis [35]. Taken together with the present study, these findings 
support the increasing evidence of the role of SDF-1/CXCR4 axis in osteosarcoma metastasis.  
Furthermore, Naml¿s et al report that infiltrating stroma (macrophages) could be the major 
source of chemokine expression in osteosarcoma [36]. ECFCs are found to be recruited into 
tumour environment as they are actively involved in tumour vascularization [17, 18]. OPG, 
previously described to be released in osteosarcoma [9], is therefore able to induce the SDF-1 
release by ECFCs in osteosarcoma environment. Suggesting that, like macrophages, ECFCs 
can also represent a source of chemokines and actively participate in tumour cells migration 
and evidencing that OPG can clearly be, directly or indirectly, involved in osteosarcoma 
metastasis development. The same role of OPG has been reported in gastric cancer by Reiko 
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et al who showed that strong expression of OPG in cancer tissue was closely associated with 
deep invasion, nodal metastasis, advanced stage and poor prognosis [37]. 
We and others have previously described the effect of OPG on new blood vessel 
formation which may occur through angiogenesis, defined as the sprouting of endothelium 
from pre-existing vasculature and involves the mature endothelial cells, or vasculogenesis in 
which entirely new vessels develop from ECFCs which circulate and ultimately contribute to 
tumour development and metastasis [38]. OPG has been shown to promote both angiogenesis 
[39, 40] and vasculogenesis since it mediates the mobilization and differentiation of ECFC 
[17, 18]. Therefore, it may ultimately have implications for tumour angiogenesis, a key 
process in cancer development. Studies conducted on the OPG involvement in osteosarcoma 
are limited and are mainly focused its role on osteoclastogenesis inhibition and related impact 
on tumour cell survival [11, 37, 41, 42]. To our knowledge, none of these studies have 
considered the possible involvement of OPG in tumour angiogenesis. In the present in vivo 
study, using a xenograft model of osteosarcoma in nude mice, was undertaken to evaluate the 
biological effects of OPG on osteosarcoma growth and vascularization. We confirmed that 
OPG alone or associated with FGF-2; a growth factor previously described to potentiate the 
OPG proangiogenic effect in vivo [17, 18], induces xenograft growth and angiogenesis 
through a SDF-1/CXCR4 axis.  
Initially, tumour growth relies on diffusion of oxygen and nutrients from the 
surrounding tissues, and donÕt need new blood vessels formation. Under these conditions, a 
tumour can grow to a size of 2Ð3 mm
3
. Thereafter, the growing metabolic needs associated 
with tumour growth are satisfied through establishment and expansion of new blood vessels. 
Tumour cells undergo the angiogenic switch, where they acquire an angiogenic phenotype 
that changes the local equilibrium between positive and negative regulators of angiogenesis, 
and stimulates the formation of new vasculatures necessary for sustainable tumour growth 
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(reviewed in [17]). In the present study, we noticed that tumours grow slowly during the first 
5 days after cell inoculation, to reach a size of 3 to 4 mm
3
, approximately. Thereafter, tumours 
size doubled in then next 3 days. This observation could be related to a beginning of 
vasculature development. Surprisingly, no significant difference was observed between the 
different groups during the first 6 days of treatment, after what the FGF-2/OPG treated 
xenografts showed exponential growth, followed by the FGF-2 and OPG treated groups. The 
apoptosis inhibitory effect, survival extension of endothelial cells and neoangiogenesis 
induced by OPG alone or associated with FGF-2 have therefore established suitable 
environment for tumour cells proliferation and consequently tumour growth. This hypothesis 
is supported by the Anti-CD31 staining which clearly revealed that xenografts treated with 
OPG alone or associated with FGF-2 displayed a greater number of blood vessels, than those 
injected with only the vehicle. Figure 7 summarizes the role of SDF-1 in the pro-tumoural 
activity of OPG. SDF-1 release by EPC located in the surrounded tissue is increased by the 
OPG secreted by cancer cells (1). It binds to CXCR4 expressed by cancer cells and allows 
these cells to attract cancer cells (3). Locally released OPG enhances the formation of blood 
vessels (4) which increases the intra-tumour vasculature and then the tumour development (5). 
In summary, our findings demonstrate that OPG contributes to the tumour growth and 
invasion by promoting tumour angiogenesis though SDF-1/CXCR4 axis in addition to its  
inhibitory effect of tumour cell apoptosis [43]. The effects of OPG on tumour 
neovascularization include increased chemotaxis of ECFCs [17, 18]. The maintain of ECFCs 
in the tumour environment can not only promote the vasculature and consequently the tumour 
growth, but also the release of cytokines and chemokines permitting potentially the tumour 
cells spread and metastasis.  
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FIGURE LEGENDS 
 
Figure 1: SDF-1 released by ECFCs after OPG exerts a strong chemoattraction on 
osteosarcoma cells.  (A) OPG markedly increased SDF-1 release by ECFCs: SDF-1 levels 
were detected by ELISA in supernatants of ECFCs pretreated or not with OPG (25 ng/mL) for 
48h. (B) SDF-1 strongly attracts MNNG-HOS cells: before the migration assay, MNNG-HOS 
cells were pretreated or not with AMD3100 (10 µg/mL) for 30 min, placed in the upper 
Boyden chambers in RPMI, 5% FCS to allow migration towards the control media (RPMI, 
5% FCS), control media with 100 ng/mL of SDF-1 (positive control), OPG (25 ng/mL) or 
supernatants of OPG-pretreated (or untreated) ECFCs placed in the lower chambers for 4h.  
MNNG-HOS cells were attracted by the conditioned media of OPG-pretreated ECFCs 
(P<0.001) with a more efficiency SDF-1 (P<0.01). This effect was strongly reduced, by 50%, 
after MNNG-HOS treatment with AMD3100 (P <0.01). 25 ng/mL of OPG stimulated 
MNNG-HOS cell chemotaxis (P <0.01). (C) SDF-1 released in the supernatants of OPG- 
pretreated ECFCs induces MNNG-HOS cell migration: MNNG-HOS cells were pretreated 
with RPMI, 5% FCS with or without 100 ng/mL of SDF-1 (positive control), 25 ng/mL of 
OPG or with supernatants of OPG-pretreated ECFCs. When required, AMD3100 (10 µg/mL) 
was added 30 min before MNNG-HOS treatment. 24h later, control and pretreated- cells in 
suspension in RPMI, 5% FCS were placed in the upper Boyden chambers to allow migration 
towards the same media placed in the lower chambers for 4h. SDF-1 alone (P <0.05) and 
SDF-1 released by ECFCs under OPG treatment (P <0.01) induces MNNG-HOS cells 
spontaneous migration. Effect of supernatants of OPG-pretreated ECFCs was reduced by 30% 
(p<0.05) when the SDF-1/CXCR4 interaction was blocked by AMD3100. Mean ± SEM, n=3, 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 2: SDF-1 released in the supernatants of OPG pretreated ECFCs modulates the 
motility of prostate cancer cells. Before the migration assay, DU145 prostate carcinoma 
cells were pretreated or not with AMD3100 (10 µg/mL) for 30 min, placed in the upper 
Boyden chambers in DMEM, 5% FCS to allow cell migration towards the control media 
(DMEM, 5% FCS), control media with 100ng/ml of SDF-1, OPG (25ng/ml) or supernatants 
of OPG pretreated (or untreated) ECFCs placed in the lower chambers during 4h.  
Conditioned media of ECFCs pretreated with OPG strongly attract tumour cells (p<0.001). 
This effect was reduced by 30% (p<0.05) when the SDF-1/CXCR4 interaction was blocked 
by AMD3100. OPG alone has no effect on the DU145 cells chemotaxis. Mean ± SEM, n=3, 
*p<0.05, **p<0.01, ***p<0.001 
 
Figure 3: OPG alone or associated with FGF-2 induces tumour growth in a xenograft 
osteosarcoma model.  MNNG-HOS cells were injected subcutaneously into mice. When 
tumours had reached approximately 3-4 mm
3
 in size, 100 µl of either 0.9% NaCl (negative 
control), mouse OPG (2 µg/Kg), mouse FGF-2 (1.4 µg/Kg) alone or supplemented with 
mouse OPG (2 µg/Kg) were administered by direct intra-tumour injection. This procedure 
was repeated twice a week for 3 weeks. Tumour volume was measured thrice per week and 
each volume (V) was calculated according to the following formula: V=a×b
2
/2 (a and b are 
the largest and smallest perpendicular tumour diameters). Relative tumour volumes (RTV) 
were calculated from the following formula: RTV=(Vx/V1); Vx is the tumour volume on day 
x and V1 is the tumour volume at initiation of treatment (day 1). (A) Example photographs of 
tumours excised from mice of each group at the endpoint. (B) Tumour growth curves as a 
function of time in peri-tumour treated with OPG (2 µg/kg) or control vehicle: a significant 
increase in OPG-treated-xenograft growth was observed from day 7 after injection (about 
90% with respect to control at the endpoint, P <0.01). (C) Tumour growth curves as a 
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function of time, peri-tumour treated with OPG (2 µg/kg), FGF-2 (1.4 µg/kg) or OPG+FGF-2: 
administration of OPG associated with FGF-2 showed a more important effect on xenograft 
growth than the injection of FGF-2 alone (P <0.05) and the OPG alone (P <0.01). Mean ± 
SEM, n = 7, *p<0.05, **p<0.01, ***p<0.001.  
 
 
Figure 4 : Co-localisation of von Willebrand factor (vWF) with CD31 and α-SMA in the 
endothelial cells of neoformed tumour blood vessels. Immunohistochemistry of VWF,  
CD31 and α-SMA coupled to confocal microscopy analysis were performed on 10 µm cutting 
temperature coumpound frozen sections of tumours from control and treated-mice. (A) anti-
CD31, (B) vWF, (C) merged picture. (D-F) Immunohistological staining of α-SMA (FITC) 
and CD31 expression in the endothelial cells of tumoural blood vessels. (D) anti-CD31, (E) α-
SMA, (F) merged picture. Note co-localisation of CD31 and a-SMA in endothelium of 
tumoural blood vessels, indicating high specificity of CD31 antibody for blood vessels. Note 
the co-localisation of CD31 with vWF and α-SMA in endothelium of tumour blood vessels, 
indicating high specificity of CD31 antibody for blood vessels. 
 
Figure 5: OPG increases tumour vascularization. 10 µm thickness sections from frozen 
tumours were stained with an anti-mouse CD31 monoclonal antibody and TOPRO-3. Images 
were recorded on a Leica TCS SP2 confocal microscope. Eight fields were examined per 
section. The vessel surface area and the number of vessels were quantified. (A) 
Representative photomicrographs of cryosections of xenograft MNNG-HOS tumours from 
Control, OPG, FGF-2 and OPG/FGF-2 mice. Vessels were stained in red with an anti-CD31 
antibody and with a secondary antibody coupled to alexa-555. Nuclei were stained with 
TOPRO-3. (B) Quantitative analysis of the vessel surface area (%, vs CTRL), showed an 
increase of tumour angiogenesis in OPG/FGF-2 group (p<0.001) followed by the FGF-2 
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(p<0.05) and the OPG (p=0.059) ones. (C) The Number of vessels per mm
2
 confirmed the 
results of the vessel surface analysis. Mean ± SEM, n=4, *p<0.05, **p<0.01, ***p<0.001. 
 
Figure 6: OPG promotes tumour development trough SDF-1/CXCR4 axis. MNNG-HOS 
cells were injected subcutaneously into mice. When tumours had reached approximately 3-4 
mm
3
 in size, 100 µl of either 0.9% NaCl (negative control), mouse OPG (2 µg/kg) with or 
without pre-injection of AMD3100 (0.5 mg/kg) the antagonist for CXCR4 (30 min before 
OPG administration) followed by one intraperitoneal administration of AMD (5 mg/kg) 8 
hours later, were administered directly into intra-tumour masses. This procedure was repeated 
twice a week during 3 weeks. Tumour volume was measured three times per week and each 
volume (V) was calculated according to the following formula: V=a×b2/2 (a and b are the 
largest and smallest perpendicular tumour diameters). Relative tumour volumes (RTV) were 
calculated from the following formula: RTV=(Vx/V1); Vx is the tumour volume on day x and 
V1 is the tumour volume at initiation of treatment (day 1). Treatment of animals with 
AMD3100 abolished the effect of OPG on tumor growth, demonstrating that SDF-1/CXCR4 
signaling is necessary for OPG-promoted tumor growth.  Mean ± SEM, n = 7, *p<0.05, 
**p<0.01, ***p<0.001. 
 
Figure 7: SDF-1 plays a key role in the biological activity of OPG in tumour 
development. OPG secreted by cancer cells (1) increases SDF-1 release by endothelial 
colony-forming cells located in the tumour microenvironment (2). Released SDF-1 binds to 
CRCX4 expressed by cancer cells and in turn exerts a chemoattractant activity on cancer cells 
(3). Concomitantly, OPG in close collaboration with endothelial colony-forming cells 
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contributes to the formation of new blood vessels (4) which increases the intra-tumour 
vasculature and then the tumour development (5). 
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